TAILIEUCHUNG - OVARIAN CANCER - A CLINICAL AND TRANSLATIONAL UPDATE

Ovarian cancer can no longer be considered one disease entity, but a heterogeneous group of diseases. Our understanding of its clinical and molecular complexity is improving nota‐ bly over the last decade. This is of utmost importance when it comes to determine the most adequate treatment strategy for each individual patient. Despite not being the most frequent tumor, ovarian cancer has the highest mortality rate amongst gynecological cancers. The ab‐ sence of specific symptoms and the lack of a universally and validated screening strategy leads to a delayed diagnosis, when the tumor has spread beyond the. | OVARIAN CANCER - A CLINICAL AND TRANSLATIONAL UPDATE Edited by Iván Diaz-Padilla Ovarian Cancer - A Clinical and Translational Update http 56234 Edited by Iván Diaz-Padilla Contributors Malgorzata Banys Natalia Krawczyk Tanja Fehm Andreas Hartkopf Junzo Kigawa Laurie Elit Clare J. Reade Laura Cortesi Vania Goncalves Janica C. Wong Ronald Fiscus Sherif Abou Elela Jean-Philippe Brosseau Sherri Stewart Ana Fernández Montes Maddalena Falagario Gennaro Cormio Vera Loizzi Doriana Scardigno Luigi E. Selvaggi Annekathryn Goodman Jeanine Staples Constantine Gennatas Alexandra Leary Alain Piché Nadzeya Gocharenko Khaider Isabelle Matte Denis Lane Claudine Rancourt Gregory Edward Rice Jorge Tapia Sebastián Illanes Mercedes De Alvarado Lucas Minig Guadalupe Patrono Iván Diaz Padilla Rafael Alvarez Gallego Javier Valero De Bernabe Gonzalo Tapia Rico Ivan Diaz-Padilla Published by InTech Janeza Trdine 9 51000 Rijeka Croatia Copyright 2013 InTech All chapters are Open Access distributed under the Creative Commons Attribution license which allows users to download copy and build upon published articles even for commercial purposes as long as the author and publisher are properly credited which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech authors have the right to republish it in whole or part in any publication of which they are the author and to make other personal use of the work. Any republication referencing or personal use of the work must explicitly identify the original source. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials instructions methods or ideas .

• Y học thường thức
• Ovarian Cancer
• Alternative Messenger
• the Next Generation
• Cancer Biomarkers
• Biological Rationale
• Therapeutic Opportunities
• BMC Cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• CD133+ cancer stem cells
• Ovarian cancer stem cells
• Boesenbergia pandurata
• Original ovarian cancer cells
• Prognostic biomarker
• Mucinous ovarian cancer
• Clear cell ovarian cancer
• Cell cycle
• Epithelial ovarian cancers
• Malignant ovarian neoplasms
• VP treatment
• Epithelial ovarian cancer
• Borderline ovarian tumor
• Sperm protein 17
• Ovarian biomarker
• Serous ovarian cancer
• Serum microRNA
• Ovarian surface epithelial cells
• Ovarian cell lines
• Epithelial mesenchymal transition
• Cancer stem cell
• Anticipated delay
• While ovarian cancer
• Symptom awareness
• Ovarian symptoms
• Serous epithelial ovarian cancer
• Ribosomal protein S4
• Breast cancer cells
• High grade serous ovarian cancer
• Breast cancer
• Low patient survival
• Cancer stem cells
• Phosphatidylinositol 3 kinase
• Phosphoinositide 3 kinase regulatory subunit 3
• Cancer antigen 125
• Non ovarian cancer
• Multivariable logistic regression
• Randomized controlled trials
• Ovarian carcinoma
• Angiogenesis biomarkers
• Ovarian neoplasms
• Biomarkers predict
• Carcinomas classified
• Recent alcohol consumption
• Ovarian borderline tumor histologic
• Survival rates
• Cox proportional hazard models
• Ovarian cancer survival
• Symptom presentation
• Health beliefs
• Increased risk
• Protein peptide profiling
• Multivariate index assay
• Risk reduction
• Histology based referral
• BRCA2 mutation carriers
• Histotype specific survival
• BRCA mutations
• Lysophosphatidic acid receptor
• Biological functions
• Metastatic ovarian cancer cell lines
• Luteinizing hormone releasing hormone
• Brucea javanica oil
• Treat ovarian cancer
• Visceral organs
• Fusion peptide
• Anti ovarian cancer
• Cell viability
• Ovarian cancer cells
• Cytotoxic T lymphocytes
• Cyclin A1
• α gal epitopes
• Ovarian cancer stem like cells
• Protein c erbB 2
• Chemo resistance
• Platinum resistance
• Receiver operator characteristics
• Ovarian cancer cell lines